Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) - Total Liabilities
Based on the latest financial reports, Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has total liabilities worth CN¥1.30 Billion CNY (≈ $190.32 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Hangzhou Bio-Sincerity Pharma-Tech Co.Lt to track the company's year-over-year net asset growth rate.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Total Liabilities Trend (2019–2025)
This chart illustrates how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Hangzhou Bio-Sincerity Pharma-Tech Co.Lt generate to measure how efficiently the company converts operating cash flow to free cash.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Competitors by Total Liabilities
The table below lists competitors of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Amarsoft Information & Technolgy Co Ltd
SHE:300380
|
China | CN¥579.91 Million |
|
Aeroflex Industries Limited
NSE:AEROFLEX
|
India | Rs1.09 Billion |
|
NV Nederlandsche Apparatenfabriek Nedap
AS:NEDAP
|
Netherlands | €60.49 Million |
|
Wuxi Xinhongtai ElecTech
SHG:603016
|
China | CN¥197.03 Million |
|
Legacy Housing Corp
NASDAQ:LEGH
|
USA | $52.48 Million |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SHE:300619
|
China | CN¥3.56 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥442.16 Million |
|
Hwang Chang General Contractor Co Ltd
TW:2543
|
Taiwan | NT$10.58 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Hangzhou Bio-Sincerity Pharma-Tech Co.Lt.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2025)
The table below shows the annual total liabilities of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.20 Billion ≈ $175.20 Million |
+4.86% |
| 2024-12-31 | CN¥1.14 Billion ≈ $167.08 Million |
+15.92% |
| 2023-12-31 | CN¥984.97 Million ≈ $144.13 Million |
+120.13% |
| 2022-12-31 | CN¥447.45 Million ≈ $65.48 Million |
-26.30% |
| 2021-12-31 | CN¥607.10 Million ≈ $88.84 Million |
+90.19% |
| 2020-12-31 | CN¥319.20 Million ≈ $46.71 Million |
+219.55% |
| 2019-12-31 | CN¥99.89 Million ≈ $14.62 Million |
-- |
About Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business cove… Read more